Navigation Links
Budesonide in Medical News

MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca

MOUNTAIN VIEW, Calif., Feb. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced that the waiting period under the Hart-Scott-Rodino Act for its Unit Dose Budesonide (UDB) worldwide agreement with AstraZeneca has expired, and the agreement is now effective. Under...

Par Pharmaceutical Begins Shipment of Budesonide Inhalation Suspension Immediately

WOODCLIFF LAKE, N.J., Nov. 19 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that it has entered into a supply and distribution agreement with AstraZeneca in the U.S. to market budesonide inhalation suspension, which is a generic form of AstraZeneca's P...

PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008

MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Con...

Addition Of Budesonide To Formoterol Reduces Risk Of Mortality

For severe COPD patients treated with budesonide added to either formoterol (Symbicort, AstraZeneca) and/or a short acting bronchodilator, there is a reduced risk of mortality// compared to patients treated with only formoterol and/or terbutaline Important new data from the analysis of combi...

MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results

... and Chief Executive Officer of MAP Pharmaceuticals. "With these positive results in hand and our recent decision to suspend development of Unit Dose budesonide (UDB), we are now focusing our efforts on the development of LEVADEX. We believe that LEVADEX has a differentiated profile, with the potential to pro...

MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration

...aq: MAPP ) today announced that it has received a notice of termination of the license agreement with AstraZeneca related to the company's Unit Dose budesonide (UDB) product candidate. The termination was received on July 8, 2009, effective immediately. All rights licensed to AstraZeneca in the agreement no...

MAP Pharmaceuticals Phase 3 Trial of LEVADEX(TM) Migraine Product Candidate Meets All Four Primary Endpoints

...ns that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and LEVADEX inhaled therapy is being developed...

MAP Pharmaceuticals Announces Presentations at the American Thoracic Society International Conference

...hat it will present three posters on its Unit Dose budesonide (UDB) pediatric asthma therapy clinical program an...ntations are titled: "Unit Dose budesonide (UDB): A New Submicron Dispersion of Nebulizable budesonide Studied in 360 Children 12 Months to 8 Years Old w...

MAP Pharmaceuticals to Present at the Deutsche Bank Securities 34th Annual Health Care Conference

...ns that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical development. Unit Dose budesonide is being developed in collaboration with AstraZeneca for the potential treatment of asthma in children, and MAP0004 is being developed for the potenti...

Santarus to Webcast Analyst Day and Investor Briefing Presentation on May 13

... European Crohn's and Colitis Organization budesonide MMX (R) - Clinical Development Program in Ulcerat...loping two late-stage lower GI product candidates, budesonide MMX(R) and rifamycin SV MMX(R) for the U.S. market. budesonide MMX is being investigated in two multi-center Phas...
Budesonide in Medical Technology

MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints

MOUNTAIN VIEW, Calif., Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) announced today results of its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma. The Company announced that the clinical trial d...

AstraZeneca's Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints

LONDON, Feb. 23 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. announced today that its initial Phase 3 clinical trial of Unit Dose Budesonide (UDB) for the potential treatment of children with asthma did not meet its co-primary endpoints: asthma control as assessed by changes from baseline i...

Meritage Pharma Initiates Phase 2b Clinical Trial of Oral Viscous Budesonide for Pediatric Patients With Eosinophilic Esophagitis

SAN DIEGO, Jan. 22 /PRNewswire/ -- Meritage Pharma, Inc. announced today that it has initiated a dose-ranging Phase 2b clinical trial to evaluate oral viscous budesonide (OVB) for the treatment of children and adolescents with eosinophilic esophagitis (EoE), an allergic inflammatory condition of t...

MAP Pharmaceuticals to Present Unit Dose Budesonide Phase 2 Clinical Data at the World Asthma Meeting

MOUNTAIN VIEW, Calif., June 22, 2007 /PRNewswire/ -- MAP Pharmaceuticals, Inc. today announced that it will present Phase 2 data from its Unit Dose Budesonide (UDB) pediatric asthma therapy clinical program at the World Asthma Meeting at the Lutfi Kirdar Convention and Exhibition Center in Istanbu...

Pivotal Data Showed SYMBICORT(R) Improved Lung Function in Adults with COPD

...c Obstructive Pulmonary Disease (COPD) relative to budesonide and formotorol administered alone, and placebo.(1,...V1 within 15 minutes with SYMBICORT as compared to budesonide and placebo on the day of randomization and end of...0/4.5 micrograms (mcg), SYMBICORT pMDI 80/4.5 mcg, budesonide pMDI 160 mcg + formoterol DPI 4.5 mcg,...

Newly Released Data on Onset of Effect and Patient Perception With SYMBICORT in Adults With Asthma

...omization (median time, 13 minutes), compared with budesonide pMDI and placebo (P<.001).(1) Time to onset of cli...atients receiving SYMBICORT versus those receiving budesonide pMDI and placebo reported feeling their study medi...ication begin to work (except for SYMBICORT versus budesonide pMDI in Study 1 [P=.073]).(1) The results seen at ...

MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion

...izing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharma...

MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine

...izing on their known safety, efficacy and commercialization history. MAP Pharmaceuticals has two drug candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharma...

Study Analyzed SYMBICORT(R) in Children with Persistent Asthma

...hose taking formoterol dry powder inhaler (DPI) or budesonide pressurized metered-dose inhaler (pMDI). Results w...ations and received two inhalations twice-daily of budesonide pMDI 40 micrograms (mcg), 128 patients(1,2) were r...s twice-daily, 145(1,2) were randomized to receive budesonide pMDI 40 mcg two inhalations twice-daily, and 138(1...

AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication

...ompared with formoterol 4.5 and in average post-dose FEV1 compared with budesonide 160, with maintenance of effect for both comparisons over the 6-month t...x 160/4.5 microgram & 80/4.5 microgram bid Compared to Formoterol TBH, budesonide pMDI (& the combination) & Placebo in COPD Patients. [CLINICAL STUDY R...
Budesonide in Biological News

Pregnant women with asthma can be more confident about some medicines

... budesonide sprays can be regarded as safe for pregnancy - oth...ma drugs they were using before they got pregnant. budesonide sprays are the best studied and can be regarded as...ed in trials that include pregnant women. However, budesonide sprays have been studied enough: women can be conf...
Budesonide in Biological Technology

Par Pharmaceutical Halts Shipment of Budesonide Inhalation Suspension

WOODCLIFF LAKE, N.J., Nov. 20 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX ) today announced that the U.S. District Court for the District of New Jersey last night granted AstraZeneca Pharmaceuticals' motion for a temporary restraining order (TRO) halting sales of Teva...

PARI Respiratory to Present New Study Comparing Nebulizers Delivering Budesonide at CHEST 2008

MIDLOTHIAN, Va., Oct. 22 /PRNewswire/ -- At CHEST 2008, PARI Respiratory Equipment will present a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZ...

Pharmalink AB Completes Phase II Clinical Study With Renal Disease Drug Nefecon(R)

... by a three month follow up period. Full results will be presented at the World Congress of Nephrology 2009, 22-26 May in Milan (Smerud et al, Enteric budesonide Ameliorates Albuminuria and Glomerular Filtration Rate in IgA Nephropathy Patients) and at the satellite meeting, IgA Nephropathy, 26-28 May in Stresa...

FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)

...ts using SYMBICORT had significantly greater mean improvements from baseline in 1-hour post-dose FEV1 averaged over the treatment period compared with budesonide 160 mcg and placebo.(2) Furthermore, the median time to onset of significant bronchodilation (greater than or equal to 15% improvement in FEV1) was fi...

MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine

...ditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of asthma in children, and MAP0004 is being developed for the potential treatment of migraine. MAP Phar...

MAP Pharmaceuticals Provides Update on Progress of Two Phase 3 Clinical Programs

...ounced continued progress with its two Phase 3 clinical programs, Unit Dose budesonide (UDB) for children with asthma and MAP0004 for the acute treatment of migra...he company has two product candidates in Phase 3 clinical trials. Unit Dose budesonide is being developed for the potential treatment of asthma in children, and M...

Pediatric Asthma Programs Featuring PARI Pharma's eFlow Acquired by AstraZeneca

...w is featured prominently in the development pipeline. Included in the AstraZeneca acquisition are the North American rights to a Captisol(R) enabled budesonide solution (controller medication), a proprietary short-acting beta-agonist solution (rescue medication), a customized version of eFlow(R) (novel aeroso...
Other Tags
(Date:7/31/2015)... ... July 31, 2015 , ... Physical therapy for knee osteoarthritis is an ... life. It keeps the patient from doing what they want or need to do. The ... time using the stairs. The patient's exercise regime may be limited by the pain in ...
(Date:7/31/2015)... ... , ... The Radiology Business Management Association’s 2015 Fall Educational ... Health Care: A View From Capitol Hill” on Sunday, Sept. 27, 2015, in Austin, ... Burgess has a special understanding of the real world impact of health care policy ...
(Date:7/31/2015)... ... July 31, 2015 , ... In the most recent testosterone lawsuit ... the Northern District of Illinois, Androgel testosterone attorneys report that a “Mini Status Conference” ... was made recording the minutes of the status conference, which was held that day, ...
(Date:7/31/2015)... ... 2015 , ... Intellitec Solutions announced today they have expanded ... GP for a senior living facility in Maine. Having achieved recognition as a ... 16 states. This further expansion was again a factor of the firm’s success ...
(Date:7/30/2015)... ... ... When responsible for the care of an aging loved one, summer vacations ... What happens if mom falls? Who will remind Dad to take his medications? What ... not taking time away from caregiving responsibilities can lead to bigger problems – caregiver ...
Breaking Medicine News(10 mins):Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 2Health News:Congressional Health Caucus Founder Rep. Michael Burgess, MD, to Speak at RBMA Fall Educational Conference 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 2Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 3Health News:Testosterone Lawsuit News: Androgel Lawsuit Conference Held 4Health News:Intellitec Solutions Expands Long term Care ERP Offerings to Maine 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 2Health News:Aging Life Care Association™ Experts Offer Tips for Caregivers in Need of Vacation Time 3
(Date:7/7/2015)... Conn. , July 7, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces a revised version ... this week. The commercial will air on CNBC in ... Los Angeles and San Francisco ... The commercial focuses on Wocket,s ability to replace all the cards ...
(Date:7/2/2015)... Research and Markets( http://www.researchandmarkets.com/research/jvft55/next_generation ... Generation Biometrics Market by Application, Technology, Function & Geography ... offering. The next generation biometrics market is ... CAGR of 17.9% between 2015 and 2020 ... market. Safran SA ( France ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 2Wocket Smart Wallet Commercials Airing on CNBC to Showcase This Summer's Must- Have Tech Product 3Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
Other Contents